Denali Therapeutics Inc (NASDAQ:DNLI) has earned an average broker rating score of 1.83 (Buy) from the three brokers that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a hold recommendation, one has assigned a buy recommendation and one has assigned a strong buy recommendation to the company.
Brokers have set a twelve-month consensus target price of $24.67 for the company and are expecting that the company will post ($0.27) earnings per share for the current quarter, according to Zacks. Zacks has also given Denali Therapeutics an industry rank of 185 out of 265 based on the ratings given to related companies.
Several equities research analysts recently weighed in on DNLI shares. Goldman Sachs started coverage on Denali Therapeutics in a report on Tuesday, January 2nd. They issued a “neutral” rating for the company. JPMorgan Chase & Co. started coverage on Denali Therapeutics in a report on Tuesday, January 2nd. They issued an “overweight” rating and a $24.00 price objective for the company. Morgan Stanley started coverage on Denali Therapeutics in a report on Tuesday, January 2nd. They issued an “overweight” rating and a $25.00 price objective for the company. Finally, Evercore ISI started coverage on Denali Therapeutics in a report on Tuesday, January 2nd. They issued an “outperform” rating and a $23.00 price objective for the company.
Denali Therapeutics stock traded up $0.17 during midday trading on Friday, hitting $21.34. The stock had a trading volume of 465,051 shares, compared to its average volume of 386,555. Denali Therapeutics has a 12 month low of $14.72 and a 12 month high of $25.79.
Denali Therapeutics (NASDAQ:DNLI) last released its earnings results on Monday, March 19th. The company reported ($0.74) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.27) by ($0.47). research analysts predict that Denali Therapeutics will post -0.87 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This report was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://www.tickerreport.com/banking-finance/3300568/zacks-denali-therapeutics-inc-dnli-given-average-recommendation-of-buy-by-brokerages.html.
Denali Therapeutics Company Profile
Denali Therapeutics Inc is a biotechnology company. The Company is focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and others. The Company is developing a diversified portfolio of therapeutics, based on scientific insights into the genetic causes and biological processes underlying neurodegenerative disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.